Pfizer to present oncology data at US conference

Pfizer is set to unveil data from a variety of clinical studies into early-stage compounds at the American Association for Cancer Research (AACR) Annual Meeting.

The pharmaceutical giant has announced plans to show results for its investigational antibody-drug conjugate (ADC) portfolio and present research that evaluates molecules targeting novel pathways that play a crucial role in basic cellular functions.

Taking place in Chicago, the AACR meeting is due to run from Saturday March 31st to Wednesday April 4th.

Last year's conference attracted more than 17,000 representatives, with 648 speakers and 252 sessions taking place over the course of the event.

Bob Abraham, senior vice-president and chief scientific officer at Pfizer's Oncology Research Unit, said the company will aim to demonstrate its "continued commitment to emerging science and to advancing research and development in the area of antibody-drug conjugates".

He added that Pfizer hopes to "discover and develop the next generation of ADCs" to improve cancer treatment options.